2157 Lepu Biopharma Co. Ltd. HKEX · China

Lepu Biopharma Co. (2157) news

Lepu Biopharma Co. Ltd. is a public biotech or pharmaceutical company listed on HKEX under the ticker 2157, recorded under China. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Lepu Biopharma Co. news

We have not published a story on Lepu Biopharma Co. yet. When there is news, it will appear here.

Questions about Lepu Biopharma Co.

What is the ticker symbol of Lepu Biopharma Co.?

Lepu Biopharma Co. Ltd. trades under the ticker 2157 on HKEX.

Where is Lepu Biopharma Co. listed?

Lepu Biopharma Co. Ltd. is listed on HKEX.

Which country or territory is Lepu Biopharma Co. listed under?

Our directory records Lepu Biopharma Co. Ltd. under China.

What does Lepu Biopharma Co. do?

Our directory classifies Lepu Biopharma Co. Ltd. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of Lepu Biopharma Co.?

The ISIN recorded for Lepu Biopharma Co. Ltd. is CNE100004SM4.

Does aibio.space cover Lepu Biopharma Co.?

aibio.space lists Lepu Biopharma Co. Ltd. among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to Lepu Biopharma Co.?

Companies in our directory listed in the same country and business area as Lepu Biopharma Co.: Jiuzhitang Co., Zhejiang Huahai Pharmaceutical Co., Ginwa Enterprise (Group), Jiangsu Hengrui Pharmaceuticals Co., Sichuan Kelun-Biotech Biopharmaceutical Co., Beijing Centergate Technologies (Holding) Co..

Investor discussion: Lepu Biopharma Co.

Members talk about Lepu Biopharma Co. (2157). Reader posts, not aibio.space reporting, and not investment advice.

Rules

Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Lepu Biopharma Co., newest first. Each line links the filing it comes from.

Apr 27, 2026Financings
Share or debt issue: (1) 2025 REPORT OF THE BOARD OF DIRECTORS (2) 2025 REPORT OF THE BOARD OF SUPERVISORS (3) 2025 ANNUAL REPORT (4) 2025 FINANCIAL ACCOUNTS REPORT (5) 2026 FINANCIAL BUDGET (6) 2025 ANNUAL PROFIT DISTRIBUTION PLAN (7) RE-APPOINTMENT OF AUDITOR (8) PROPOSED APPOINTMENT OF SUPERVISOR (9) PROPOSED CHANGE OF REGISTERED ADDRESS (10) PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION (11) GENERAL MANDATE TO ISSUE ADDITIONAL SHARES AND NOTICE OF THE 2025 ANNUAL GENERAL MEETING. Source
Jul 11, 2025Financings
Share or debt issue: COMPLETION OF PLACING OF NEW H SHARES UNDER GENERAL MANDATE. Source
Jul 4, 2025Financings
Share or debt issue: PLACING OF NEW H SHARES UNDER GENERAL MANDATE. Source
Jun 6, 2025Financings
Share or debt issue: (1) 2024 REPORT OF THE BOARD OF DIRECTORS (2) 2024 REPORT OF THE BOARD OF SUPERVISORS (3) 2024 ANNUAL REPORT (4) 2024 FINANCIAL ACCOUNTS REPORT (5) 2025 FINANCIAL BUDGET (6) 2024 ANNUAL PROFIT DISTRIBUTION PLAN (7) RE-APPOINTMENT OF AUDITOR (8) PROPOSED APPOINTMENT OF NON-EXECUTIVE DIRECTOR (9) GENERAL MANDATE TO ISSUE ADDITIONAL SHARES AND NOTICE OF THE 2024 ANNUAL GENERAL MEETING. Source

Press releases

Headlines of Lepu Biopharma Co.'s own announcements, newest first. Each opens the full release on the newswire that carried it.

Oct 26, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT CMG901 (AZD0901) CLINICAL RESULTS PRESENTED AS LBA PROFFERED PAPER AT PRESIDENTIAL SYMPOSIUM, MRG007 CLINICAL RESULTS PRESENTED AS LBA, AND ENCOURAGING DATA FOR MRG003 PRESENTED AS RAPID ORAL AT ESMO 2026
Sep 23, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT FOUR CLINICAL STUDIES SELECTED FOR PRESENTATION AT 2026 ESMO CONGRESS: CMG901 (AZD0901) CLINICAL TRIAL RESULTS SELECTED AS LBA FOR PROFFERED PAPER PRESENTATION AT PRESIDENTIAL SYMPOSIUM, MRG007 CLINICAL TRIAL RESULTS SELECTED AS LBA FOR RAPID ORAL PRESENTATION, AND TWO OTHER STUDIES SELECTED FOR RAPID ORAL PRESENTATION
Aug 19, 2026HKEXnews
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026
Jul 28, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT POSITIVE TOP-LINE RESULTS ACHIEVED FROM CLARITY-GASTRIC01 GLOBAL PHASE III TRIAL OF CMG901 (AZD0901)
Jul 15, 2026HKEXnews
CHANGE OF EMPLOYEE REPRESENTATIVE SUPERVISOR
May 19, 2026HKEXnews
ARTICLES OF ASSOCIATION
May 19, 2026HKEXnews
(1) POLL RESULTS OF THE 2025 ANNUAL GENERAL MEETING HELD ON MAY 19, 2026; (2) APPOINTMENT OF SUPERVISOR; (3) CHANGE OF REGISTERED ADDRESS AND (4) AMENDMENTS TO THE ARTICLES OF ASSOCIATION
May 6, 2026HKEXnews
DIS-APPLICATION OF RULES 18A.09 TO 18A.11 OF THE LISTING RULES AND REMOVAL OF STOCK MARKER
Apr 27, 2026HKEXnews
(1) PROPOSED APPOINTMENT OF SUPERVISOR; (2) PROPOSED CHANGE OF REGISTERED ADDRESS; AND (3) PROPOSED AMENDMENTS OF THE ARTICLES OF ASSOCIATION
Apr 27, 2026HKEXnews
(1) 2025 REPORT OF THE BOARD OF DIRECTORS (2) 2025 REPORT OF THE BOARD OF SUPERVISORS (3) 2025 ANNUAL REPORT (4) 2025 FINANCIAL ACCOUNTS REPORT (5) 2026 FINANCIAL BUDGET (6) 2025 ANNUAL PROFIT DISTRIBUTION PLAN (7) RE-APPOINTMENT OF AUDITOR (8) PROPOSED APPOINTMENT OF SUPERVISOR (9) PROPOSED CHANGE OF REGISTERED ADDRESS (10) PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION (11) GENERAL MANDATE TO ISSUE ADDITIONAL SHARES AND NOTICE OF THE 2025 ANNUAL GENERAL MEETING
Apr 27, 2026HKEXnews
NOTICE OF THE 2025 ANNUAL GENERAL MEETING
Mar 25, 2026HKEXnews
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025
Mar 10, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT UPDATE ON COLLABORATION WITH ASTRAZENECA FOR ADC CANDIDATE CMG901 (AZD0901)
Mar 10, 2026HKEXnews
POSITIVE PROFIT ALERT
Dec 18, 2025HKEXnews
UPDATES ON LICENSING TRANSACTION
Dec 18, 2025HKEXnews
POLL RESULTS OF THE 2025 SECOND EXTRAORDINARY GENERAL MEETING HELD ON DECEMBER 18, 2025
Dec 2, 2025HKEXnews
AMENDMENTS TO THE ARTICLES OF ASSOCIATION
Nov 28, 2025HKEXnews
NOTICE OF THE SECOND 2025 EGM
Nov 28, 2025HKEXnews
(1) PROPOSED ADOPTION OF THE RESTRICTED SHARE UNIT SCHEME (H SHARE); AND (2) NOTICE OF THE SECOND 2025 EGM
Nov 28, 2025HKEXnews
CONTINUING CONNECTED TRANSACTION CDMO SERVICES FRAMEWORK AGREEMENT

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open HKEX:2157 on TradingView.

Listing details

Company: Lepu Biopharma Co. Ltd.
Ticker: 2157
Listing: HKEX
Country or territory: China
Business scope: Pharmaceuticals: Major
ISIN: CNE100004SM4
Last quote in directory: 2026-10-22
Directory source: Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction